お知らせ • Mar 27
Numinus Wellness Provides Update Regarding Listing Status Numinus Wellness Inc. is providing an update regarding its listing status on the Toronto Stock Exchange ("TSX"). As previously disclosed in the Company's management information circular dated July 29, 2025, and as approved by shareholders at the Company's annual general meeting held on August 28, 2025 (with voting results subsequently disclosed on September 3, 2025), shareholders authorized the Board of Directors, in its discretion, to voluntarily delist the Company's common shares from the TSX if deemed to be in the best interests of the Company. Further to Numinus' news release of March 13, 2026, on March 19, 2026 the Continued Listing Committee of the TSX met and determined to delist the Company's common shares from the TSX, effective April 22, 2026. While this delisting does not result from a request from the Company, it is consistent with the authorization of the shareholders to delist Numinus from the TSX, and aligns with the Company's previously disclosed strategic considerations. As the Company remains subject to a cease trade order (the "CTO"), the delisting from the TSX will not change the current trading status of its securities, which are not presently tradable in Canada. The Company will continue to be a reporting issuer in all applicable Canadian jurisdictions. Looking ahead for Numinus, management is pleased to advise that an application has been filed to list the Company's shares on the Canadian Securities Exchange (the "CSE"). If approved, a listing on the CSE could only take effect after the CTO has been revoked. The listing of the Company's common shares on the CSE is subject to the Company meeting the CSE's listing requirements, which cannot be guaranteed. Management remains focused on: completing the work to have the audit completed for the Company's financial statements for the year ended August 31, 2026; satisfying all regulatory requirements necessary to have the CTO revoked; and advancing an application to list its common shares on the CSE. Successfully executing these steps remains management's primary strategy to restore trading, enhance shareholder liquidity, and position the Company for its next phase of growth. お知らせ • Jul 14
Numinus Wellness Inc., Annual General Meeting, Aug 28, 2025 Numinus Wellness Inc., Annual General Meeting, Aug 28, 2025. お知らせ • Dec 18
Stella MSO, Inc. completed the acquisition of Five Wellness Clinics from Numinus Wellness Inc. (TSX:NUMI). Stella MSO, Inc. signed a definitive agreement to acquire Five Wellness Clinics from Numinus Wellness Inc. (TSX:NUMI) for $3.5 million on November 15, 2024. A cash consideration of $2.08 million will be paid by Stella MSO, Inc. Stella MSO, Inc. will pay a deferred payment of $0.75 million cash paid over six equal monthly instalments in 2025 and of $0.7 million cash to be paid in 2025. The transaction is expected to close on or before November 30, 2024.
Stella MSO, Inc. completed the acquisition of Five Wellness Clinics from Numinus Wellness Inc. (TSX:NUMI) on December 17, 2024. お知らせ • Jul 11
Numinus Wellness Inc. to Report Q3, 2024 Results on Jul 11, 2024 Numinus Wellness Inc. announced that they will report Q3, 2024 results After-Market on Jul 11, 2024 お知らせ • Jun 08
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD Numinus Wellness Inc. comments on the results of June 4, 2024 meeting of the U.S. Food and Drug Administration's ("FDA") Psychopharmacologic Drugs Advisory Committee ("PDAC"). The independent committee reviewed Lykos Therapeutics' new drug application for MDMA (midomafetamine capsules) used in combination withpsychological intervention for individuals with post-traumatic stress disorder ("PTSD"). The PDAC voted against recommending approval of MDMA for PTSD in a majority decision where 2 of 11 found that the available data demonstrates MDMA's effectiveness in PTSD patients, and one committee member found that the benefits of MDMA outweigh its risks for treating PTSD patients based on available data. The FDA is expected to decide on Lykos' new drug application in August this year and is not bound by the PDAC's guidance. Advisory committees, like PDAC, make non-binding recommendations to the FDA. Historically, between 2010 and 2021, the FDA approved subject treatments in 97% of cases where the committee recommended approval and in 33% of cases where the committee recommended against approval. 1 There can be no assurance as to the FDA's decision with respect to Lykos' MDMA new drug application. Pending the approval of new medications for the treatment of mental health conditions, Spravato® (esketamine), and ketamine continue to be available to practitioners. The Numinus US clinic network has delivered over 43,600 such treatments to patients. Through the auspices of Health Canada's Special Access Program, Numinus clinics have also treated several patients with MDMA and psilocybin in Canada. Through Cedar Clinical Research, Numinus has conducted clinical research involving four psychedelic medicines administered through different modalities involving 50 subjects over the past 2.5 years. At the same time, company's comprehensive practitioner training program prepares the Numinus team and trainees to treat patients across multiple medications and modalities, including ketamine and MDMA. お知らせ • May 30
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy Numinus Wellness Inc. announced that Health Canada has approved the Company's Clinical Trial Application to examine the feasibility of a group model in MDMA-assisted psychotherapy enrolling trainee practitioners as participants. The study aims to enhance comprehension of the ideal number of therapists needed to administer MDMA-assisted psychotherapy group sessions effectively. Additionally, the trial offers eligible trainees the chance to develop core competencies through observing seasoned therapists conduct MDMA-assisted psychotherapy sessions and legally experience MDMA themselves in a therapeutic setting as healthy research subjects. The clinical trial is formally titled "Phase 1 Exploration of Feasibility and Optimal Therapist Numbers in Group Model MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and Practitioner Training. お知らせ • Apr 10
Numinus Wellness Inc. to Report Q2, 2024 Results on Apr 15, 2024 Numinus Wellness Inc. announced that they will report Q2, 2024 results After-Market on Apr 15, 2024 お知らせ • Mar 20
Numinus Wellness Inc. Submits Clinical Trial Application Numinus Wellness Inc. announced that it has submitted a Clinical Trial Application to Health Canada to examine the feasibility of a group model in MDMA-assisted psychotherapy enrollee practitioners as participants. If approved, the trial would allow Numinus to study MDMA-assisted psychotherapy with groups and better understand the optimum number of therapists required to deliver the programs safely. It may also provide eligible trainees with the opportunity to build core competencies and legally experience MDMA. The clinical trial is formally titled Phase 1 Exploration of Feasibility and Optimal Therapist Numbers in Group Model MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and Practitioner Training. If approved, it will be the first of its kind. お知らせ • Feb 16
Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 6 million. Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 6 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 50,000,000
Price\Range: CAD 0.12 お知らせ • Dec 19
Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024 Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024. お知らせ • Nov 22
Numinus Wellness Inc. to Report Q4, 2023 Results on Nov 29, 2023 Numinus Wellness Inc. announced that they will report Q4, 2023 results After-Market on Nov 29, 2023 お知らせ • Oct 05
Numinus Wellness Inc. Introduces Its Innovative and Comprehensive Psychedelic Program for Individuals Surging from Mental Distress Associated with Chronic and Serious Illness Through Cedar Clinical Research Numinus Wellness Inc. introduced its innovative and comprehensive psychedelic program for individuals suffering from mental distress associated with serious and chronic illness. Operating out of the Numinus Wellness UT and Cedar Clinical Research facilities, the program encompasses four key initiatives that showcase Numinus' commitment to advancing psychedelic research and its potential for healing. Group Psilocybin Pilot Study Numinus Chief Science Officer, Dr. Paul Thielking, is the senior author of a recently published study of the safety, feasibility, and possible efficacy of group-administered psilocybin for depressed cancer patients. This study not only demonstrates the possible therapeutic benefits of psilocybin but also highlights the immense potential the group model holds for reducing the costs associated with psychedelic therapy. Numinus has also completed a group ketamine-assisted therapy intervention pilot for subjects suffering from chronic and serious illnesses. This pilot project showcased the effectiveness of ketamine-assisted therapy in alleviating depression and psychological distress associated with these conditions. This endeavor underscores Numinus' commitment to exploring innovative psychedelic-assisted therapy models for patients in need of new treatment options. Group Psilocybin Project Building on the success of the ketamine pilot project and the group psilocybin study, Numinus is thrilled to announce an upcoming follow-up group psilocybin project. Approved by both the U.S. Food and Drug Administration (FDA) and an Institutional Review Board (IRB), this study will, among other things, reduce the therapist to patient ratio while continuing to evaluate the impact of psilocybin-assisted therapy on cancer patients with depression. Subject to the availability of legal psilocybin- assisted therapy under applicable law, the results of this research may contribute to reducing costs and enhancing access for this patient population in the future. お知らせ • Jun 30
Numinus Wellness Inc. to Report Q3, 2023 Results on Jul 17, 2023 Numinus Wellness Inc. announced that they will report Q3, 2023 results After-Market on Jul 17, 2023 お知らせ • Jun 15
Numinus Wellness Inc. Appoints Nikhil Handa as Chief Financial Officer, Effective from June 15, 2023 Numinus Wellness Inc. announced the appointment of Nikhil Handa as Chief Financial Officer, effective June 15, 2023, following a thorough executive search. Current Chief Financial Officer, John Fong, will be stepping down effective end of day to focus on family health matters. Mr. Fong will remain involved with the Company during the incoming CFO transition period to ensure a seamless transfer of responsibilities. Most recently, Mr. Handa was CFO at The Supreme Cannabis Company Inc., where he led finance, investor relations and corporate development. At Supreme, Mr. Handa led the restructuring of the company to focus on profitable growth, and was responsible for executing the sale of Supreme to Canopy Growth Corporation. Prior to this, he led finance at Well.ca, a leading digital health and wellness company. In that role he led the finance function, provided leadership across various aspects of operations and drove key strategic initiatives including the sale of Well.ca to McKesson Canada. Over the course of his career, Mr. Handa also held a variety of senior finance and operational roles at Restaurant Brands International. Mr. Handa was part of the mergers and acquisition group of RBC Capital Markets, where he helped advise the management teams and board of directors of private and public companies on various types of transactions across Canada, the U.S., and globally. お知らせ • Jun 06
Numinus Wellness Inc. Announces Cedar Clinical Research Numinus Wellness Inc. announced Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder. CCR's research clinic in Draper, Utah, is the top enrolling site for the research study - having enrolled and dosed 19 clinical trial participants for the study to date. CCR also recently began enrolling volunteers for this trial at a second research clinic - in Murray, Utah. The MindMed study aims to enroll up to 200 participants who will receive a single administration of 25 ug, 50 ug, 100 ug or 200 ug of MM-120 or placebo. Topline results are expected to be announced by MindMed in late 2023. お知らせ • May 31
Numinus Wellness Inc. Announces to Research COMP360 Psilocybin Therapy in Treatment-Resistant Depression as Part of Large Phase 3 Study Numinus Wellness Inc. announced that Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an investigational new therapy for treatment-resistant depression (TRD), as part of the largest-ever international clinical study of psilocybin therapy. Dr. Paul Thielking, Chief Science Officer at Numinus, and the team have begun accepting people with TRD who fulfill certain eligibility criteria to join the study. The study in Draper, Utah, is a part of COMPASS Pathway's phase 3 program in TRD. The international program is composed of two pivotal trials, each with a long-term follow-up component. It will enroll over 800 participants, with top line data expected in summer 2024 and mid-2025. The launch of the phase 3 program follows positive results from COMPASS Pathways' phase 2b trial, published in the New England Journal of Medicine, the world's leading peer-reviewed medical journal. The objective of the randomized, controlled, double-blind phase 2b study was to understand the efficacy and safety of a single dose of investigational COMP360 psilocybin (25mg or 10mg), compared to 1mg, in patients with TRD. After a single 25mg dose of COMP360 psilocybin, in combination with psychological support, 29.1% of participants with TRD were in remission by week 3. お知らせ • May 26
Numinus Wellness Inc Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy Numinus Wellness Inc. announced several recent initiatives aimed at best positioning the company for the expected FDA approval of MDMA-assisted therapy ("MDMA-AT") in the United States in the first half of 2024. In anticipation of this regulatory approval, Numinus has undertaken several initiatives to prepare the company for a rapid rollout of MDMA-AT services (using the MAPS protocol), including the recently launched Numinus NetworkTM clinic expansion program, reallocation of resources towards revenue producing activities, cost containment initiatives, and preparation for insurance reimbursement systems. お知らせ • Feb 02
Numinus Wellness Inc. Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training Using Psilocybe Cubensis Tea Numinus Wellness Inc. announced that it has received approval from Health Canada for its experiential training study that will test the safety and clinical efficacy of whole Psilocybe cubensis tea for therapeutic use, and enable practitioners to further their understanding of psychedelic-assisted therapy through experiential training. The clinical trial, formally titled A Phase 1, Open-Label, Single-Arm Study to Evaluate Psilocybin Experiential Training in Healthy Volunteers and Expand Knowledge and Qualifications of Therapists Planning to Conduct Psilocybin-Assisted Therapy (NUMT2), will initially be conducted at Numinus' clinic in Vancouver, and will begin selecting volunteers in the next several weeks. Study subjects will be selected from practitioners who have trained or are currently training to provide psilocybin-assisted therapy through Numinus' Practitioner Training Program or other approved training programs. Initial results from the study are expected to be published in the second half of 2023. The protocol for the clinical trial will include three sessions per study participant: one preparatory session, one dosing session, and one integration session, which will be followed by an observation period and participant interviews and questionnaires. Over the course of the clinical trial, each experiential training study volunteer will participate both as a study participant receiving the protocol and as an observer for another participant's sessions. The clinical trial will use Numinus Bioscience's EnfiniTea, a whole mushroom Psilocybe tea product delivering 25mg of psilocybin to patients when administered as directed, for trial dosing. EnfiniTea is produced using Numinus' own validated strain of Psilocybe cubensis BP-Star, and is uniquely shelf stable, consistently dosed and economical to produce. The product has also been submitted to Health Canada to be included on the psilocybin supplier list for the federal Special Access Program, through which health care providers can apply to provide psilocybin-assisted therapy, among other psychedelic-assisted therapies, to patients with demonstrable need. お知らせ • Jan 05
Numinus Wellness Inc. to Report Q1, 2023 Results on Jan 16, 2023 Numinus Wellness Inc. announced that they will report Q1, 2023 results After-Market on Jan 16, 2023 お知らせ • Dec 20
Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023 Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023.